Home / Companies / Vera Therapeutics, Inc. / 21 May 2026
Vera Therapeutics, Inc.: meeting of 21 May 2026
Votes reported on Form N-PX, item by item
333 Form N-PX filers reported votes at the Vera Therapeutics, Inc. meeting of 21 May 2026. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
3 nominees; 78.7% of reported votes for; 60 filers withheld from or voted against at least one nominee.
639 vote records from 115 filers. 20 of the 115 filers that marked the item either way voted against management.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
504 vote records from 331 filers. 30 of the 312 filers that marked the item either way voted against management. 19 filers reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
210 vote records from 114 filers. 1 of the 114 filers that marked the item either way voted against management.
How the largest families voted
| Family | 1. Directors | 2. Say-on-pay | 3. Auditor |
|---|---|---|---|
| Vanguard | For | For | For |
| BlackRock and iShares | For | For | For |
| Fidelity | For | For | For |
| Dimensional | Abstain or withhold * | For | For |
| State Street and SPDR | For | For | For |
| American Century | For | Against * | For |
| Franklin Templeton | No report | For | No report |
| Invesco | For | Against * | For |
| Equitable | For | For | For |
| Charles Schwab | For | For | For |
| Nuveen and TIAA | For | For | For |
| ProShares and ProFunds | For | For | For |
| John Hancock and Manulife | For | For | For |
| Morgan Stanley, Eaton Vance and Calvert | Abstain or withhold * | For | For |
| J.P. Morgan | For | For | For |
| Goldman Sachs | For | For | For |
| PGIM and Prudential | For | For | For |
| Northern Trust and FlexShares | Abstain or withhold * | For | For |
| SEI | For | For | For |
| T. Rowe Price | For | For | For |
| Lincoln Financial | For | For | For |
| Voya | Abstain or withhold * | For | For |
| Russell Investments | For | For | For |
| Nationwide | For | For | For |
| Victory Capital | For | For | For |
| Brighthouse Funds | For | For | For |
| Guggenheim and Rydex | For | For | For |
| Columbia Threadneedle | For | For | For |
| BNY Mellon | For | For | For |
| Principal | Abstain or withhold * | For | For |
| Pacific Life funds | For | For | For |
| Global X | For | For | For |
| MFS | No report | For | No report |
| Transamerica | For | For | For |
| AllianceBernstein | Abstain or withhold * | For | For |
| DWS | Abstain or withhold * | For | For |
| Allspring | No report | Split or no vote | No report |
| MassMutual | No report | For | No report |
| Neuberger Berman | No report | For | No report |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Vera Therapeutics, Inc. meeting?
333 Form N-PX filers reported votes at the meeting of 21 May 2026. On say-on-pay, 30 of 312 voted against management (9.6%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Vera Therapeutics, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Vera Therapeutics, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Vera Therapeutics, Inc. with a meeting date within three days of 21 May 2026. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.